Recent Updates
Recently added Catalysts

Epithelial Ovarian Carcinoma: one US-listed biotech with a clinical-stage programme

OncologyUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$2.6Buniverse median $1.20B
Allocated capital$1.3B$2.6B competing
Phase 3 or filed00 mid, 1 early
Pure plays0this indication only
Capital rank127/299crowding rank 146

Epithelial Ovarian Carcinoma is uncontested. Nurix Therapeutics (NRIX) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with NX-1607 in phase 1.

There is no public comparable to price it against. NRIX spreads its $2.6B market cap across 2 indications, so $1.3B of it is allocated here.

Nothing here has reached Phase 3: 0 programmes in mid stage and 1 in early stage, so the field is still several years from a first approval.

$1.3B of allocated capital sits in Epithelial Ovarian Carcinoma, ranking it 127th of 299 indications by the money committed to it.

Companies developing drugs for Epithelial Ovarian Carcinoma 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
NRIXNurix TherapeuticsNX-1607Phase 11$2.6BNo2No dated event

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Epithelial Ovarian Carcinoma counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Epithelial Ovarian Carcinoma has one competitor and a median of $2.6B.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Myelofibrosis3 companies · $1.3B · median $1.8BConcentrated betAdvanced Renal Cell Carcinoma1 company · $1.3B · median $14.7BUncontestedCastrate-resistant Prostate Cancer1 company · $1.3B · median $14.7BUncontestedHead and Neck Neoplasms1 company · $1.3B · median $14.7BUncontestedPancreatic Neuroendocrine Tumors1 company · $1.3B · median $14.7BUncontestedMetastatic Small Cell Lung Cancer1 company · $1.3B · median $4.0BUncontestedUrothelial Cancer1 company · $1.4B · median $1.4BUncontestedSoft-tissue Sarcoma2 companies · $1.5B · median $4.0BConcentrated bet

Epithelial Ovarian Carcinoma pipeline questions

Which biotech companies are developing drugs for Epithelial Ovarian Carcinoma?

Nurix Therapeutics (NRIX, NX-1607, Phase 1). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Epithelial Ovarian Carcinoma.

How advanced is the Epithelial Ovarian Carcinoma pipeline?

Of the 1 clinical-stage programme in Epithelial Ovarian Carcinoma, 0 are in Phase 3 or filed, 0 are in mid-stage development and 1 is in early-stage development.

Is anyone else developing a drug for Epithelial Ovarian Carcinoma?

No. NRIX is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Epithelial Ovarian Carcinoma, which is why the indication is classified as uncontested.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map